Third Quarter 2026
Filed Oct 30, 2026BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance
Third-quarter revenue, gross profit, income from continuing operations and Adjusted EBITDA all increased year over year, while the company increased full-year Revenue and Adjusted EBITDA guidance. Pharmacy revenue per script, Home Health Care average daily census and both segment EBITDA measures increased, and leverage declined from June 30, 2026.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, three months ended September 30GAAP | $4.21B | – | 26% |
| Total revenue, nine months ended September 30GAAP | $11.70B | – | 25% |
| Gross profit, three months ended September 30GAAP | $518.5M | – | – |
| Gross profit, nine months ended September 30GAAP | $1.49B | – | – |
| Selling, general, and administrative expenses, three months ended September 30GAAP | $358.1M | – | – |
| Selling, general, and administrative expenses, nine months ended September 30GAAP | $1.08B | – | – |
| Operating income, three months ended September 30GAAP | $160.5M | – | – |
| Operating income, nine months ended September 30GAAP | $412.3M | – | – |
| Income from continuing operations, net of income taxes, three months ended September 30GAAP | $100.8M | – | – |
| Income from continuing operations, net of income taxes, nine months ended September 30GAAP | $261.7M | – | – |
| Net income, three months ended September 30GAAP | $100.3M | – | – |
| Net income, nine months ended September 30GAAP | $333.1M | – | – |
| Diluted income per share attributable to common shareholders from continuing operations, three months ended September 30GAAP | $0.46 | – | – |
| Diluted income per share attributable to common shareholders from continuing operations, nine months ended September 30GAAP | $1.18 | – | – |
| Diluted net income per share, three months ended September 30GAAP | $0.45 | – | – |
| Diluted net income per share, nine months ended September 30GAAP | $1.51 | – | – |
| Adjusted EPS, three months ended September 30non-GAAP | $0.54 | – | – |
| Adjusted EPS, nine months ended September 30non-GAAP | $1.37 | – | – |
| Pharmacy Solutions Segment EBITDA, three months ended September 30non-GAAP | $202M | – | 43% |
| Pharmacy Solutions Segment EBITDA, nine months ended September 30non-GAAP | $551M | – | 45% |
| Provider Services Segment EBITDA, three months ended September 30non-GAAP | $79M | – | 30% |
| Provider Services Segment EBITDA, nine months ended September 30non-GAAP | $220M | – | 31% |
| Total Segment EBITDA, three months ended September 30non-GAAP | $281M | – | 39% |
| Total Segment EBITDA, nine months ended September 30non-GAAP | $771M | – | 40% |
| Corporate Costs, three months ended September 30non-GAAP | −$53M | – | n.m. |
| Corporate Costs, nine months ended September 30non-GAAP | −$148M | – | n.m. |
| Total Company Adjusted EBITDA, three months ended September 30non-GAAP | $228M | – | 42% |
| Total Company Adjusted EBITDA, nine months ended September 30non-GAAP | $623M | – | 44% |
| Prescriptions dispensed, three months ended September 30other | 10,949,875 | – | 2% |
| Revenue per script, three months ended September 30other | 340.86 | – | 24% |
| Gross Profit per script, three months ended September 30other | 28.86 | – | 27% |
| Home Health Care average daily census, three months ended September 30other | 47,256 | – | 58% |
| Rehab Care persons served, three months ended September 30other | 7,574 | – | 9% |
| Personal Care persons served, three months ended September 30other | 16,320 | – | 1% |
| Net cash provided by operating activities, three months ended September 30GAAP | $204.3M | – | – |
| Net cash provided by operating activities, nine months ended September 30GAAP | $371.2M | – | – |
| Purchases of property and equipment, three months ended September 30GAAP | −$22.09M | – | – |
| Purchases of property and equipment, nine months ended September 30GAAP | −$72.67M | – | – |
| Leverage as of September 30, 2026other | 1.79x | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Pharmacy Solutions, three months ended September 30Prescriptions dispensed were 10,949,875, revenue per script was 340.86, and gross profit per script was 28.86. | $3.73B | – | 26% |
| Provider Services, three months ended September 30Home Health Care average daily census was 47,256; Rehab Care persons served were 7,574; Personal Care persons served were 16,320. | $481M | – | 31% |
| Pharmacy Solutions, nine months ended September 30Prescriptions dispensed were 32,523,789, revenue per script was 317.03, and gross profit per script was 28.13. | $10.31B | – | 24% |
| Provider Services, nine months ended September 30Home Health Care average daily census was 46,898; Rehab Care persons served were 7,345; Personal Care persons served were 16,253. | $1.39B | – | 30% |
Full Year 2026 outlook
- Revenue$15,900 million to $16,125 million
- Note23.2% to 24.9% growth
- NotePharmacy Segment Revenue of $14,000 million to $14,200 million, or 22.3% to 24.1% growth
- NoteProvider Segment Revenue of $1,900 million to $1,925 million, or 29.7% to 31.4% growth
- NoteTotal Adjusted EBITDA of $850 million to $860 million, or 37.6% to 39.3% growth
- NoteThe Amedisys and LHC branches acquisition is expected to contribute approximately $35 million in Adjusted EBITDA in 2026
Capital returns
- Repurchases of shares of common stock: $(120,000) thousand for the nine months ended September 30, 2026.
What drove it
- Pharmacy Solutions revenue increased 26% to $3,732 million in the third quarter; revenue per script increased 24% to 340.86 and gross profit per script increased 27% to 28.86.
- Provider Services revenue increased 31% to $481 million in the third quarter, with Home Health Care average daily census increasing 58% to 47,256.
- Pharmacy Solutions Segment EBITDA increased 43% to $202 million and Provider Services Segment EBITDA increased 30% to $79 million.
- Adjusted EBITDA increased 42% to $228 million in the third quarter.
- Effective July 1, 2026, the company realigned its Rehab in Motion business from the Rehab Care sub-segment to the Home Health Care sub-segment. Prior period sub-segment information was recast; the change did not affect consolidated company or segment results.
Concerns
- Corporate Costs were $(53) million in the third quarter, compared with $(41) million in the third quarter of 2025.
- Personal Care persons served were 16,320, up 1% from 16,134 in the third quarter of 2025.
- Prescriptions dispensed were 10,949,875, up 2% from 10,793,219 in the third quarter of 2025.
- Accounts receivable, net of allowance for credit losses, was $1,216,377 thousand as of September 30, 2026, compared with $989,719 thousand as of December 31, 2025.
- The guidance excludes the Community Living business and the effects of any future closed acquisitions.
What to watch
- Delivery against full-year Revenue guidance of $15,900 million to $16,125 million.
- Delivery against full-year Total Adjusted EBITDA guidance of $850 million to $860 million.
- The expected approximately $35 million Adjusted EBITDA contribution in 2026 from the Amedisys and LHC branches acquisition.
- Pharmacy revenue per script and gross profit per script, given prescriptions dispensed increased 2% in the third quarter.
- Provider Services census and persons-served trends following the Rehab in Motion realignment.
Balance sheet and cash flow
- Cash and cash equivalents: $717,840 thousand as of September 30, 2026, compared with $88,370 thousand as of December 31, 2025.
- Long-term debt, net of current portion: $2,146,779 thousand as of September 30, 2026, compared with $2,455,204 thousand as of December 31, 2025.
- Current portion of long-term debt: $35,277 thousand as of September 30, 2026, compared with $52,340 thousand as of December 31, 2025.
- Total assets: $6,266,621 thousand as of September 30, 2026, compared with $6,413,311 thousand as of December 31, 2025.
- Total liabilities: $4,080,806 thousand as of September 30, 2026, compared with $4,526,945 thousand as of December 31, 2025.
- Total shareholders' equity: $2,176,540 thousand as of September 30, 2026, compared with $1,875,065 thousand as of December 31, 2025.
- Long-term debt repayments: $(332,300) thousand for the nine months ended September 30, 2026, compared with $(37,933) thousand for the nine months ended September 30, 2025.
- Proceeds from sale of discontinued operations: $810,908 thousand for the nine months ended September 30, 2026.
- Net cash provided by investing activities: $696,003 thousand for the nine months ended September 30, 2026, compared with $(71,195) thousand for the nine months ended September 30, 2025.
- Net cash used in financing activities: $(437,821) thousand for the nine months ended September 30, 2026, compared with $(107,368) thousand for the nine months ended September 30, 2025.
Analysis
BrightSpring reported third-quarter total revenue of $4,213,234 thousand, compared with $3,334,106 thousand in the prior-year quarter. Gross profit was $518,549 thousand versus $392,008 thousand, while operating income was $160,480 thousand versus $87,843 thousand. Income from continuing operations, net of income taxes, was $100,802 thousand, compared with $37,488 thousand. The company stated that all financial results provided pertain to continuing operations following the March 30, 2026 divestiture of the Community Living business.
Both operating segments expanded. Pharmacy Solutions revenue was $3,732 million, up 26%, while Provider Services revenue was $481 million, up 31%. In Pharmacy, prescriptions dispensed rose 2%, while revenue per script rose 24% to 340.86 and gross profit per script rose 27% to 28.86. In Provider Services, Home Health Care average daily census increased 58% to 47,256, while Rehab Care persons served increased 9% and Personal Care persons served increased 1%.
Profitability growth exceeded reported revenue growth in the company’s non-GAAP measures. Pharmacy Solutions Segment EBITDA increased 43% to $202 million, Provider Services Segment EBITDA increased 30% to $79 million, and Total Company Adjusted EBITDA increased 42% to $228 million. Corporate Costs were $(53) million, compared with $(41) million. Diluted income per share from continuing operations was $0.46 and Adjusted EPS was $0.54, compared with $0.17 and $0.30, respectively, in the prior-year quarter.
Cash generation and the balance sheet reflected significant movement during the nine-month period. Net cash provided by operating activities was $371,181 thousand, compared with $258,610 thousand. Cash and cash equivalents were $717,840 thousand as of September 30, 2026, and long-term debt, net of current portion, was $2,146,779 thousand. Leverage was 1.79x as of September 30, 2026, compared with 2.15x on June 30, 2026. The company repurchased $(120,000) thousand of common stock and made $(332,300) thousand of long-term debt repayments during the nine months ended September 30, 2026.
Management increased full-year 2026 Revenue guidance to $15,900 million to $16,125 million and Total Adjusted EBITDA guidance to $850 million to $860 million. The guide excludes Community Living and the effects of any future closed acquisitions. It includes expected approximately $35 million of Adjusted EBITDA contribution in 2026 from the Amedisys and LHC branches acquisition. The central reported operating issues to monitor are whether Pharmacy can sustain revenue and gross-profit-per-script gains, whether Provider census growth continues, and whether corporate costs remain contained as the company pursues the increased guidance.
Management, verbatim
Our third quarter results again reflect the commitment of our team to patient care and operational execution across our Pharmacy and Provider businesses.
Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring
We have a differentiated company, our value proposition for healthcare stakeholders is clear, and our confidence in the future remains high, supported by a broad set of process and growth drivers across a uniquely scaled and high-quality platform.
Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring
As we progress through 2026, we believe that BrightSpring is well -positioned to make a greater and greater impact and deliver durable growth in 2027 and beyond.
Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring
Not in the filing
stated, not guessed- Prior-quarter total revenue, gross profit, operating income, net income, EPS and Adjusted EBITDA were not reported.
- GAAP gross margin was not reported.
- Free cash flow was not reported.
- Dividend amounts or dividend declarations were not reported.
- Full-year 2026 guidance for gross margin, operating expenses and tax rate was not reported.
- Prior guidance was not provided, so comparison with prior guidance is unavailable.
- A quantitative reconciliation of full-year Adjusted EBITDA guidance to GAAP net income from continuing operations was not provided; the company stated it could not be provided without unreasonable effort.
- Year-over-year percentage changes were not printed for gross profit, operating income, income from continuing operations, net income, GAAP EPS, Adjusted EPS, operating cash flow, capital expenditures, cash or debt.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.